Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy.

Thrombosis Research
Alessandro Di MinnoMatteo Nicola Dario Di Minno

Abstract

Treatment with protein convertase subtilisin kexin type 9 inhibitors (PCSK-9i) reduced cholesterol levels and cardiovascular events in patients with hypercholesterolemia. We assessed changes in lipid profile, oxidation markers and endothelial function in patients with familial hypercholesterolemia (FH) after a 12-week treatment with a PCSK-9i. Patients with FH starting a treatment with PCSK-9i were included. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) (Lp(a)), small dense LDL (assessed by LDL score), 11-dehydro-thromboxane (11-TXB2), 8-isoprostaglandin-2alpha (8-iso-PGF2α), flow-mediated dilation (FMD) and reactive hyperaemia index (RHI) were evaluated before starting PCSK-9i treatment and after a 12-week treatment. Twenty-five subjects were enrolled (52% males, mean age 51.5 years). At the 12-week assessment, we observed a 38% median reduction in TC, 52% in LDL-C, 7% in Lp(a) and 46% in LDL score. In parallel, 11-TXB2 and 8-iso-PGF2α showed a reduction of 18% and 17%, respectively. FMD changed from 4.78% ± 2.27 at baseline to 10.6% ± 5.89 at 12 weeks (p < 0.001), with RHI changing from 2.37 ± 1.23 to 3.76 ± 1.36 (p < 0.001). A multivariate analysis showed that, after adjusting for potent...Continue Reading

References

Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Sep 19, 2003·Journal of the American College of Cardiology·Sammy Y ChanAndrew Ignaszewski
Dec 8, 2004·Journal of the American College of Cardiology·Piero O BonettiAmir Lerman
Mar 25, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Belay Tesfamariam
Nov 7, 2006·Journal of the American College of Cardiology·Ann E DonaldJulian P Halcox
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Nov 1, 2011·Thrombosis Research·Matteo Nicola Dario Di MinnoGiovanni Di Minno
Jun 20, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·Yicong YeShuyang Zhang
Sep 20, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Satoshi Hirayama, Takashi Miida
Oct 9, 2012·International Journal of Cardiology·Rouyanne T RasPeter L Zock
Sep 3, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Marco GentilePaolo Rubba
Mar 19, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Christos G MihosOrlando Santana
Oct 14, 2014·Molecular and Cellular Probes·Maria Donata Di TarantoGiuliana Fortunato
Jan 30, 2015·Circulation. Cardiovascular Genetics·Nathan O StitzielSekar Kathiresan
Apr 26, 2015·Journal of Clinical Lipidology·James M McKenney
Mar 22, 2016·Biomarkers in Medicine·Marco GentilePaolo Rubba
May 18, 2016·British Journal of Pharmacology·Andreas DaiberThomas Münzel
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 23, 2017·European Heart Journal·Sophie J Bernelot MoensErik S G Stroes
Apr 15, 2017·Journal of the American College of Cardiology·Francesco PaneniGiovanni G Camici
Oct 3, 2017·Atherosclerosis. Supplements·Angela PirilloUNKNOWN LIPIGEN Group
Feb 6, 2018·Scientific Reports·Chiara RicciNicola Ferri
Mar 17, 2018·Journal of Clinical Lipidology·Guglielmo MaulucciNatale Daniele Brunetti
Jun 22, 2018·JAMA Cardiology·Stephen BurgessUNKNOWN European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium
Oct 3, 2018·Atherosclerosis·Manuela CasulaUNKNOWN STUDY CENTRAL LABORATORY AND ANALYSIS GROUP
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Dec 31, 2018·Redox Biology·Anders L SørensenChristina Ellervik

❮ Previous
Next ❯

Citations

Dec 2, 2020·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Ilenia CalcaterraMatteo N D Di Minno
May 1, 2021·Journal of Clinical Medicine·Gabriella IannuzzoFrancesco Giallauria
Jun 3, 2021·International Journal of Molecular Sciences·Cristina BaraleIsabella Russo
Aug 28, 2021·Biomedicines·Pasquale AmbrosinoMatteo Nicola Dario Di Minno
Nov 2, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Francesco GiallauriaCarmine Morisco

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.